Cantor Fitzgerald Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $165.00

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) had its price objective reduced by investment analysts at Cantor Fitzgerald from $178.00 to $165.00 in a research report issued on Friday, The Fly reports. Cantor Fitzgerald’s price target would suggest a potential upside of 34.49% from the company’s previous close.

Other analysts also recently issued reports about the stock. UBS Group upgraded shares of Sarepta Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $100.00 to $158.00 in a report on Friday, December 16th. Barclays boosted their target price on shares of Sarepta Therapeutics from $149.00 to $170.00 in a report on Wednesday, March 1st. BTIG Research boosted their target price on shares of Sarepta Therapeutics from $125.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, December 22nd. JPMorgan Chase & Co. boosted their target price on shares of Sarepta Therapeutics from $153.00 to $206.00 and gave the stock an “overweight” rating in a report on Friday, March 3rd. Finally, Cowen upped their price target on shares of Sarepta Therapeutics from $114.00 to $125.00 in a report on Wednesday, January 11th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $165.88.

Sarepta Therapeutics Stock Down 18.0 %

Shares of NASDAQ SRPT opened at $122.69 on Friday. The company has a current ratio of 4.13, a quick ratio of 3.80 and a debt-to-equity ratio of 4.01. The firm’s fifty day moving average is $129.49 and its two-hundred day moving average is $120.17. Sarepta Therapeutics has a 52-week low of $61.28 and a 52-week high of $159.84.

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last announced its quarterly earnings results on Tuesday, February 28th. The biotechnology company reported ($1.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.28) by $0.04. Sarepta Therapeutics had a negative net margin of 75.40% and a negative return on equity of 117.29%. The company had revenue of $258.43 million for the quarter, compared to the consensus estimate of $250.51 million. During the same period in the previous year, the firm posted ($1.42) EPS. Sarepta Therapeutics’s revenue for the quarter was up 28.3% compared to the same quarter last year. On average, analysts forecast that Sarepta Therapeutics will post -4.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. FourThought Financial LLC lifted its position in Sarepta Therapeutics by 43.5% during the third quarter. FourThought Financial LLC now owns 297 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 90 shares during the last quarter. AQR Capital Management LLC increased its stake in Sarepta Therapeutics by 3.5% during the 4th quarter. AQR Capital Management LLC now owns 2,826 shares of the biotechnology company’s stock valued at $366,000 after purchasing an additional 95 shares in the last quarter. Exchange Traded Concepts LLC increased its stake in Sarepta Therapeutics by 16.5% during the 4th quarter. Exchange Traded Concepts LLC now owns 685 shares of the biotechnology company’s stock valued at $89,000 after purchasing an additional 97 shares in the last quarter. Utah Retirement Systems increased its stake in Sarepta Therapeutics by 0.7% during the 3rd quarter. Utah Retirement Systems now owns 14,971 shares of the biotechnology company’s stock valued at $1,654,000 after purchasing an additional 100 shares in the last quarter. Finally, Neuberger Berman Group LLC increased its stake in Sarepta Therapeutics by 2.5% during the 3rd quarter. Neuberger Berman Group LLC now owns 4,250 shares of the biotechnology company’s stock valued at $470,000 after purchasing an additional 105 shares in the last quarter. 87.31% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

(Get Rating)

Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.